Combining an existing drug with chemotherapy can suppress an aggressive type of breast cancer’s resurgence, a study published Tuesday found. The study, published in The New England Journal of Medicine, found that treating patients with both Keytruda, an immunotherapy drug, and chemotherapy prior to surgery reduced the chances of disease recurrence for early triple-negative breast cancer by 37 percent when compared with patients treated solely with chemotherapy. Lead researcher Peter Schmid, a professor at Queen Mary University of London, said, “The estimates are that, just in the US where this treatment was recently approved by the Food and Drug Administration, this new treatment may save as many as 10,000 lives per year.”
Unlock a year of full access to The Daily Beast for $35.
Monthly
$1
First monththen $5.99/month
Unlimited access (web + app)
Exclusive ad-free newsletters
Commenting access
Daily crossword
Sneak peek of launches & events
Auto-renews at $5.99 monthly. Cancel anytime
Annual
$35
First yearthen $59.99/year
Discounted annual rate - Save 47%
Unlimited access (web + app)
Exclusive ad-free newsletters
Commenting access
Daily crossword
Sneak peek of launches & events
Auto-renews at $59.99 yearly. Cancel anytime
Best Value
Premium
$79
First yearthen $119.99/year
Discounted annual rate
Full access to the Daily Beast Substack ($60 value)*
Premium ad-free reading
Unlimited access (web + app)
Exclusive ad-free newsletters
Commenting access
Daily crossword
Sneak peek of launches & events
Auto-renews at $119.99 yearly. Cancel anytime
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Looks like you already have a subscription!
You're all set!
Thanks for subscribing.
Subscription$0.00
Total$0.00
OR
Loading subscription options
Register below to read this article for free or subscribe to unlock unlimited access to The Daily Beast.
Monthly
$1
First monththen $5.99/month
Unlimited access (web + app)
Exclusive ad-free newsletters
Commenting access
Daily crossword
Sneak peek of launches & events
Auto-renews at $5.99 monthly. Cancel anytime
Annual
$35
First yearthen $59.99/year
Discounted annual rate - Save 47%
Unlimited access (web + app)
Exclusive ad-free newsletters
Commenting access
Daily crossword
Sneak peek of launches & events
Auto-renews at $59.99 yearly. Cancel anytime
Best Value
Premium
$79
First yearthen $119.99/year
Discounted annual rate
Full access to the Daily Beast Substack ($60 value)*
Premium ad-free reading
Unlimited access (web + app)
Exclusive ad-free newsletters
Commenting access
Daily crossword
Sneak peek of launches & events
Auto-renews at $119.99 yearly. Cancel anytime
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.